EBI3

Across TCGA pan-cancer cohorts, EBI3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EBI3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher EBI3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EBI3 expression acts as an unfavorable survival marker.

STAD, PRAD, and SKCM are the cancer types where EBI3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.501	0.677	.001	21	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
SKCM	DFS	Median	All	0.222	0.760	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EBI3–STAD (OS)

Open the STAD breakdown →